24/7 Market News Snapshot 18 November, 2024 – REGENXBIO Inc. (NASDAQ:RGNX)

November 18, 2024

DENVER, Colo., 18 November, 2024 (247marketnews.com) – (NASDAQ:RGNX) are discussed in this article.
REGENXBIO Inc. (RGNX) is currently facing a notable decline in its stock performance, trading at approximately $10.705 after opening at $11.11, marking an approximate drop of 11.16%. This decrease follows the previous session closing at $9.63, highlighting a period of volatility in investor sentiment. The trading volume has reached 2.07 million shares, indicating increased market activity potentially influenced by recent news or upcoming earnings reports. Analysts are advised to monitor critical support at $9.63 and resistance at $11.11, as the company navigates these fluctuations.

In contrast, REGENXBIO is making significant progress in the therapeutic arena with its pioneering gene therapy, RGX-202, aimed at treating Duchenne muscular dystrophy (Duchenne). The company has secured alignment with the U.S. Food and Drug Administration (FDA) for its pivotal AFFINITY DUCHENNE® program, which could pave the way for an expedited Biologics License Application (BLA) filing anticipated in 2026.

The Phase I/II trial, which targets ambulatory patients aged one and older, has successfully enrolled its first participant. Preliminary data indicates promising efficacy outcomes, with treated patients across two dosing levels demonstrating functional enhancements that surpass established clinical thresholds according to the North Star Ambulatory Assessment (NSAA). Moreover, biomarker findings have shown reliable expression of the RGX-202 microdystrophin in muscle tissue, reinforcing the therapy’s potential benefits.

REGENXBIO’s President and CEO, Curran M. Simpson, expressed enthusiasm regarding the positive trajectory of RGX-202, emphasizing the therapy’s capability to significantly alter the disease course for boys with Duchenne. As the company advances through this pivotal clinical stage, REGENXBIO is committed to expanding the reach of RGX-202 to meet the substantial unmet medical needs within the Duchenne community.

Related news for (RGNX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.